Beactica startar CNS-projekt med Janssen

Samarbetet inom fragmentbaserad läkemedelsutveckling utökas.

Skånskt samarbete ska hitta nya substanser mot folksjukdomar

Lundabolagen Saromics Biostructures och Red Glead Discovery startar läkemedelsprojekt som riktar sig mot epigenetiska dysfunktioner.

Creative antibiotics rensar i portföljen

Avbryter utvecklingssamarbete med norska Qotics.

Creative antibiotics breddar portföljen

Tecknar nytt samarbetsavtal. Har tredubblat antalet projekt på ett år.

How to be a perfect mingler

Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, networking is about meeting and talking to people face-to-face," says mingling expert Mia Forsgren.

International models among science parks

Science parks have become a part of modern communities. With science parks in Oxford, Cambridge and Nice setting good examples, a special potential emerged. Countries with a clear research goal are investing in new parks, and in China, the number is growing exponentially.

Discovery of new role for leukemia gene

Martin Bergö and his colleagues have studied two gene variants that often occur in acute leukemias. One gene codes for the protein RAS, which accelerates cell division in several cancers.

Mingling do's and don'ts

Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, networking is about meeting and talking to people face-to-face," says mingling expert Mia Forsgren at Begriplig.

Gabor Fischer, Distribution Sales Manager Europe, Ismatec

Why are you going to Scanlab+Biotech Forum?

Symphogen buys tumor blocking technology

The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.

Lundbeck divests companies

The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.

Pfizer lays a chunky bid on Wyeth

that may lead to lay-offs of some 8,000 persons.

Medicult needs a word of advice

Medicult Board retains advisers, regarding the previous offer from Vitrolife.

Lytix calls in cash

Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.

Danisco strengthens its IP team

Danisco's division Genencor has appointed a new Vice President of Intellectual Property Strategy and Chief IP Counsel.

Metabolic pro heads prefect post

The dean of the Department of Biomedicine at the Sahlgrenska Academy has appointed a new assistant prefect.

Swedish nanotech crosses the Atlantic

Genovis signs distribution agreement Finnzymes in US.

Infidelity produces faster sperms

Until now, it has been difficult to prove that fast-swimming sperms have an advantage when it comes to fertilizing an egg.

Abbott expands by acquisition

An acquisition gives Abbott a leadership position in another large and growing medical device segment.

Finnish Innovation Fund gets new leader

The Supervisory Board of the Finnish Innovation Fund Sitra has appointed members of the Board, including a new president.

Medicult acquires embryo scanner

The Danish company Medicult signs an agreement with Novocellus to gain access to embryo selection technology.

Trio goes in for high tech medicines

The Swedish drug discovery company Beactica announces fragment-based drug discovery research collaboration with GE Healthcare and the University of Uppsala.

Fat cells' reaction differs with body weight

The fat cells of overweight people may react differently to dietary changes than in their lean peers, according to a pioneering study from the Dutch organization TNO Quality of Life.

Sales Representative, Applied Biosystems